ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.

Features

Auto Apply Resume Optimizer Cover Letter Optimizer Interview Prep

Company

Social Media

Need Help?

team@applyblast.com

Director, Preclinical Immunology at Kernal Biologics, Inc. - ApplyBlast

Director, Preclinical Immunology

Kernal Biologics, Inc.

2 months ago

Boston, Massachusetts, United States

Onsite

Full Time

Director

0 applicants

View Job Listing

Apply to 100+ jobs

About this role

Kernal Bio is seeking an experienced immunology leader to head its mRNA therapeutics preclinical development efforts. The role will design and oversee pharmacology, toxicology, and DMPK studies for in‑vivo CAR‑T programs, collaborate with cross‑functional teams, and manage regulatory filings and external partners. The candidate will guide timelines, budgets, and scientific strategy in a fast‑paced biotech startup.

Responsibilities

Lead preclinical immunology efforts for mRNA therapeutics
Design and oversee pharmacology, toxicology, and DMPK studies for in vivo CAR‑T programs
Manage CROs and coordinate regulatory filings with FDA, EMA, and TGA

Skills

Qualifications

PhD in toxicology, pharmacology, immunology, immuno‑oncology, genetics or related fieldM.D./Ph.D.

About Kernal Biologics, Inc.

kernalbio.com

Headquarters

Cambridge, Massachusetts, United States

Company Size

11-50 employees

Founded

2016

View Profile

Kernal Biologics is an onco-selective mRNA therapeutics company based in Cambridge, MA that develops in vivo cell therapies by programming cells directly inside the body through targeted delivery and selective translation. Their platform uses state-of-the-art AI models to ensure selective mRNA translation in target cells, enabling scalable in vivo CAR-T therapies for patients with cancer and auto-immune diseases. Kernal overcomes the manufacturing, cost, and accessibility limitations of current ex vivo cell therapies and has received up to $48 million in funding from ARPA-H to advance its pipeline.